Home
Login Register
> Return

Go to Forum     Add To MyCorner

IX Biopharma42C

0.02 No Change

Group

Cash   

Cash

Singapore Dollar   

28-Apr 09:06

 

TRADING INFO

Open

0.02   

Buy

0.02   

High

0.02   

Low

0.02   

Previous Close

0.02   

Volume(K)

63.8   

Buy Volume(K)

17.1   

Sell Volume(K)

17.1   

 

KEY STOCK INFO

PE Ratio

NA   

Dividend Yield

-   

Price to Book Ratio

-   

Market Cap

-   

Enterprise Value

-   

52 Weeks High

0.04745904   

52 Weeks Low

0.016   

RSI

51.16 ( No Info )   

Williams %R

51.16 ( No Info )   

 

COMPANY INFORMATION Financial Info by

SIC

IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES   

Address

20 COLLYER QUAY, #11-07 SINGAPORE 049319   

Phone

(65) 6235 2170   

Fax

(65) 8928 8467   

SIC

The principal activities of the Company are the development, manufacture and commercialisation of innovative therapies for the treatment of acute and breakthrough pain, and male erectile dysfunction.   

AUDITOR

PRICEWATERHOUSECOOPERS LLP   

 

FINANICALS INFORMATION All values in $millions

  
    

Financial Year

2023-06-30   

Currency

SGD   
KEY RATIOS

Operating Margin(%)

-159.564   

Return on Equity Capital(%)

-54.023   

Net Profit Margin(%)

-162.608   

Current Ratio

1.53   

Debt to Capital at Book

0.174   
INCOME STATEMENT

EBITDA

-7482.0   

EBITDA

-6669.0   

Net Profit

-9615.0   

Ordinary Dividend

0.0   
BALANCE SHEET

Intangibles

0.291   

Fixed Assets

7.23   

Long Term Investments

0.189   

Stock/Inventories

956.0   

Cash

6519.0   

Current Liabilities

7175.0   

Long Term Debt

568.0   

Provisions

39.0   

Minorities

0.0   

Total Shareholder Equity

15.852   
PER SHARE INFO

EBITDA per share

-0.01   

EBIT per share

-0.013   

Profit per share

-0.013   

Book Value per share

0.02   

Financial Year

2024-06-30   

Currency

SGD   
KEY RATIOS

Operating Margin(%)

-160.144   

Return on Equity Capital(%)

-106.914   

Net Profit Margin(%)

-181.138   

Current Ratio

0.892   

Debt to Capital at Book

0.356   
INCOME STATEMENT

EBITDA

-6005.0   

EBITDA

-7034.0   

Net Profit

-10794.0   

Ordinary Dividend

0.0   
BALANCE SHEET

Intangibles

0.295   

Fixed Assets

7.12   

Long Term Investments

0.126   

Stock/Inventories

1380.0   

Cash

1771.0   

Current Liabilities

7381.0   

Long Term Debt

403.0   

Provisions

40.0   

Minorities

0.0   

Total Shareholder Equity

4.34   
PER SHARE INFO

EBITDA per share

-0.008   

EBIT per share

-0.013   

Profit per share

-0.014   

Book Value per share

0.005   

Financial Year

2023-06-30   

Currency

SGD   
KEY RATIOS

Operating Margin(%)

-159.564   

Return on Equity Capital(%)

-54.023   

Net Profit Margin(%)

-162.608   

Current Ratio

1.53   

Debt to Capital at Book

0.174   
INCOME STATEMENT

EBITDA

-7482.0   

EBITDA

-8411.0   

Net Profit

-9615.0   

Ordinary Dividend

0.0   
BALANCE SHEET

Intangibles

1.47   

Fixed Assets

7.23   

Long Term Investments

0.0   

Stock/Inventories

956.0   

Cash

6519.0   

Current Liabilities

7175.0   

Long Term Debt

568.0   

Provisions

39.0   

Minorities

0.0   

Total Shareholder Equity

15.852   
PER SHARE INFO

EBITDA per share

-0.01   

EBIT per share

-0.013   

Profit per share

-0.013   

Book Value per share

0.019   
Important: Please read our Terms and Conditions and Privacy Policy .